Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Sanofi: 5-Star Dividend Stocks Poised to Outperform

By Brian D. Pacampara, CFA - Nov 20, 2012 at 11:26AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Market-trouncing returns could be written in this 5-Star.

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, French pharmaceutical giant Sanofi ( SNY 0.74% ) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Sanofi and see what CAPS investors are saying about the stock right now.

Sanofi facts

Headquarters (founded)

Paris (1970)

Market Cap

$114.4 billion

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$46.9 billion

Management

CEO Christopher Viehbacher (since 2008)
CFO Jermoe Contamine (since 2009)

Return on Equity (average, past 3 years)

7.3%

Cash/Debt

$6 billion / $21 billion

Dividend Yield

4%

Competitors

GlaxoSmithKline ( GSK 1.49% )Merck ( MRK -1.55% )Pfizer ( PFE 0.47% )

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 981 members who have rated Sanofi believe the stock will outperform the S&P 500 going forward.

Just last week, one of those Fools, flynthewest, succinctly summed up the Sanofi bull case for our community:

Attach "Europe based" to nearly any company in this fall of 2012, and expect a measurable price discount. Add to that [Sanofi's] history of drug development and management coupled with the change growing population of drug consumers (read, more baby boomers aging), and you have a winner.

If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its five-star rating, Sanofi may not be your top choice.

If that's the case, we've compiled a special free report for investors called "Secure Your Future With 9 Rock-Solid Dividend Stocks," which uncovers several other juicy income opportunities. The report is 100% free, but it won't be around forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$47.91 (0.74%) $0.35
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$72.28 (-1.55%) $-1.14
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.72 (0.47%) $0.24
GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
GSK
$42.38 (1.49%) $0.62

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
633%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.